BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

negativeNegative

AI Analysis

Summary

BioMarin has discontinued a drug acquired as part of its $270M Inozyme Pharma takeover for ENPP1 deficiency after Phase 3 results showed biomarker improvements that did not translate to clinical benefit.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Drug discontinued from $270M Inozyme acquisition; Phase 3 study showed biomarker benefits but failed to translate to clinical improvements

Importance:6/10

Sentiment:

-0.80

asset discontinuationacquisitionPhase 3 failurerare metabolic diseasebiomarker vs clinical endpoint disconnect

Related Companies

$BMRN

Read the original article

Published by BioSpace on August 10, 2026 11:20 AM

Read Original